a Department of Biostatistics, School of Public Health, Graduate School of Medicine , The University of Tokyo , Tokyo , Japan.
b Department of Healthcare Information Management , The University of Tokyo Hospital , Tokyo , Japan.
Expert Opin Drug Saf. 2018 Nov;17(11):1071-1079. doi: 10.1080/14740338.2018.1528224. Epub 2018 Oct 4.
To apply a causal analysis approach to estimate the intent-to-treat and per-protocol effects in a safety outcome study of the 30-day risk of liver injury associated with antibiotic use (macrolides, penicillin-based antibiotics, and fluoroquinolones).
For each antibiotic class, we constructed a pooled cohort of treated episodes matched with untreated episodes using an electronic medical record database from a university hospital. High-dimensional propensity scores were calculated using baseline patient characteristics, concomitant medications and medical history as surrogate confounders. Intent-to-treat hazard ratios (HRs) were estimated using inverse probability of treatment weighted discrete hazard models that ignored subsequent treatment changes. Per-protocol HRs were calculated using inverse probability of treatment and censoring weighted models after terminating each episode's observation at the first treatment change.
For macrolides, the intent-to-treat HR (95% confidence interval) was 1.22 (0.75-1.98) and the per-protocol HR was 1.22 (0.67-2.22). For penicillin-based antibiotics, the intent-to-treat HR was 4.01 (3.16-5.08) and the per-protocol HR was 7.25 (5.58-9.41). For fluoroquinolones, the intent-to-treat HR was 1.60 (1.27-2.03) and the per-protocol HR was 1.69 (1.23-2.30).
Researchers should clearly define the target estimands, and carefully estimate and interpret both effects.
应用因果分析方法估计与抗生素使用相关的 30 天肝损伤风险的安全性结局研究中的意向治疗和方案治疗效果(大环内酯类、青霉素类抗生素和氟喹诺酮类)。
对于每种抗生素类别,我们使用来自大学医院的电子病历数据库,将治疗发作的合并队列与未治疗发作的合并队列进行匹配。使用基线患者特征、伴随药物和病史作为替代混杂因素计算高维倾向评分。使用忽略随后治疗变化的逆概率治疗加权离散风险模型估计意向治疗危险比(HR)。使用在每个发作的观察结束时终止第一次治疗变化的逆概率治疗和 censoring 加权模型计算方案治疗 HR。
对于大环内酯类,意向治疗 HR(95%置信区间)为 1.22(0.75-1.98),方案治疗 HR 为 1.22(0.67-2.22)。对于青霉素类抗生素,意向治疗 HR 为 4.01(3.16-5.08),方案治疗 HR 为 7.25(5.58-9.41)。对于氟喹诺酮类,意向治疗 HR 为 1.60(1.27-2.03),方案治疗 HR 为 1.69(1.23-2.30)。
研究人员应明确界定目标估计值,并仔细估计和解释两种效果。